Type 1 diabetes trials in Australia.
Studies in this index with Australian locations listed in the registry, including completed and closed studies. Overall trial status is separate from recruitment at an individual Australian site. Expand a trial to see local site details and when its registry information was checked.
This is a curated index, not a complete list of Australian research or a promise of access. Use the registry contact details to confirm whether a site is accepting participants and whether you meet the eligibility criteria.
Phase-3 trial testing whether oral baricitinib can delay progression to clinical stage-3 T1D in at-risk stage-1b/2 children and adults.
Phase
Overall status
Recruiting
Listed locations
US · UK · EU · CA · AU · JP · OTHER
Advances
Baricitinib (JAK1/2 inhibitor)
Phase-3 trial testing baricitinib in children and adults newly diagnosed with stage-3 T1D, following the positive BANDIT phase-2 result.
Phase
Overall status
Recruiting
Listed locations
US · UK · EU · CA · AU · JP · OTHER
Advances
Baricitinib (JAK1/2 inhibitor)
Sanofi's large Phase 3 confirmatory trial for teplizumab in newly diagnosed stage-3 type 1 diabetes. It is recruiting 723 participants aged 1-25 within 56 days of diagnosis and…
Phase
Overall status
Recruiting
Listed locations
US · UK · EU · CA · AU · JP · OTHER
Advances
Teplizumab for new-onset T1D (Tzield)
Novo Nordisk phase 3 trial comparing once-weekly insulin icodec with once-daily glargine U100, both with insulin aspart, in adults with type 1 diabetes.
Phase
Overall status
Active, not recruiting
Listed locations
US · EU · CA · AU · OTHER
Advances
Once-weekly insulin icodec (Awiqli)
A large international Phase 3 trial (TrialNet) testing whether a daily oral insulin capsule could delay or prevent type 1 diabetes in autoantibody-positive relatives of people…
Phase
Overall status
Completed
Listed locations
US · UK · EU · CA · AU
Advances
Oral insulin (antigen-specific immunotherapy)
TrialNet/NIDDK phase-2 trial comparing two selective oral JAK-pathway drugs - abrocitinib and ritlecitinib - with placebo for preservation of C-peptide in newly diagnosed T1D.
Phase
Overall status
Active, not recruiting
Listed locations
US · CA · AU
Advances
Selective JAK inhibitors (abrocitinib / ritlecitinib)
Phase 2 study of SAB-142, a human anti-thymocyte globulin intended to permit repeat dosing. Part A assesses safety, Part B evaluates C-peptide at 12 months after two courses six…
Phase
Overall status
Recruiting
Listed locations
US · UK · EU · AU · OTHER
Advances
SAB-142 (fully human anti-thymocyte globulin)
A TrialNet Phase 2 trial testing whether a short course of the B-cell-depleting antibody rituximab-pvvr, followed by the co-stimulation blocker abatacept, preserves the body's own…
Phase
Overall status
Active, not recruiting
Listed locations
US · AU
Advances
Abatacept (CTLA4-Ig)
Recruiting Australian Phase 2 placebo-controlled clamp study of six weeks of weekly 2.5 mg tirzepatide in adults with T1D on AID. It is a mechanistic follow-on to TIRTLE1, not a…
Phase
Overall status
Recruiting
Listed locations
AU
Advances
Tirzepatide as an adjunct in T1D
A phase 2 randomized, placebo-controlled trial testing whether baricitinib — an oral JAK1/JAK2 inhibitor already used for rheumatoid arthritis — can protect the body's own insulin…
Phase
Overall status
Completed
Listed locations
AU
Advances
Baricitinib (JAK1/2 inhibitor)
Multicenter phase-2 trial of the oral tyrosine kinase inhibitor imatinib in adults within 100 days of diagnosis. It met the 12-month C-peptide endpoint, but the effect was not…
Phase
Overall status
Completed
Listed locations
US · AU
Advances
Imatinib (tyrosine kinase inhibitor)
Completed Australian phase-2 randomized trial of low-dose weekly tirzepatide versus placebo alongside insulin. It found a large 12-week weight and insulin-dose signal, but was too…
Phase
Overall status
Completed
Listed locations
AU
Advances
Tirzepatide as an adjunct in T1D
A TrialNet prevention trial testing whether the inexpensive oral immune-modulating drug hydroxychloroquine could slow the earliest stage of type 1 diabetes in people with two or…
Phase
Overall status
Terminated
Listed locations
US · UK · EU · CA · AU
Advances
Hydroxychloroquine for stage-1 T1D prevention
Study evaluating ketone thresholds intended to minimize ketosis risk for people with T1D using dapagliflozin.
Phase
Overall status
Not yet recruiting
Listed locations
AU
Recruiting Australian Phase 1, randomised, double-blind, placebo-controlled study of subcutaneous proinsulin peptide/calcitriol liposomes (ASITI-201) in adults with stage 3 T1D.…
Phase
Overall status
Recruiting
Listed locations
AU
Advances
ASITI-201 (proinsulin peptide / calcitriol liposomes)
Immunocore Phase 1/1b single- and multiple-ascending-dose study of IMC-S118AI, a pre-proinsulin × PD-1 ImmTAAI molecule, in HLA-A*02:01-positive people with Type 1 diabetes who…
Phase
Overall status
Not yet recruiting
Listed locations
UK · AU
Advances
IMC-S118AI (PPI × PD-1 ImmTAAI)
MiniMed pivotal safety study of the system now publicly launched as MiniMed Flex and still registered under the NMX8-AID name, paired with the DS5 / Simplera Sync sensor.…
Phase
Overall status
Active, not recruiting
Listed locations
US · AU · OTHER
Advances
MiniMed Flex (formerly NMX8-AID)
The backbone US/international screening and natural-history study that tests blood from relatives of people with T1D for islet autoantibodies, then monitors those who test…
Phase
Overall status
Recruiting
Listed locations
US · UK · EU · CA · AU
Advances
Islet autoantibody screening (GADA, IA-2A, ZnT8A, IAA)
A randomized non-inferiority trial in adults with type 1 diabetes testing an open-source automated insulin delivery system run with no meal announcement at all — no carb counting,…
Phase
Overall status
Completed
Listed locations
AU · OTHER
Advances
OpenAPS (oref0)